Market Cap
Company ProfileAlphamab Oncology Market Cap History
Market Cap: HK$11.33 Billion
HKD as of Jul 30, 2026 | US$1.45 Billion
Company Profile $9966Alphamab Oncology Market Capitalization Over Time
Evolution of Alphamab Oncology market cap history
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Yearly Market Cap Evolution
| Date | Market Cap | YoY Change |
|---|---|---|
| Jan. 1, 2026 | HK$10.39 B | 218.90% |
| Jan. 1, 2025 | HK$3.26 B | -45.36% |
| Jan. 1, 2024 | HK$5.96 B | -53.32% |
| Jan. 1, 2023 | HK$12.77 B | 39.28% |
| Jan. 1, 2022 | HK$9.17 B | -24.96% |
| Jan. 1, 2021 | HK$12.22 B | -3.76% |
| Jan. 1, 2020 | HK$12.70 B |
Market capitalization is calculated from the opening stock price at the beginning of each year.
Company Description
ProfileAlphamab Oncology develops, manufactures, and commercializes biologic cancer therapies, including bispecific antibodies and other immune-oncology treatments.
What is Market Capitalization?
The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.